The successes achieved by chimeric antigen receptor-modified T （CAR-T） cells in hematological malignancies raised the pos- sibility of their use in non-small lung cancer （NSCLC）. In this phase I clinical study （N...The successes achieved by chimeric antigen receptor-modified T （CAR-T） cells in hematological malignancies raised the pos- sibility of their use in non-small lung cancer （NSCLC）. In this phase I clinical study （NCT01869166）, patients with epidermal growth factor receptor （EGFR）-positive （〉50% expression）, relapsed/refractory NSCLC received escalating doses of EGFR-targeted CAR-T cell infusions. The EGFR-targeted CAR-T cells were generated from peripheral blood after a 10 to 13-day in vitro expansion. Serum cytokines in peripheral blood and copy numbers of CAR-EGFR transgene in peripheral blood and in tissue biopsy were monitored periodically. Clinical responses were evaluated with RECISTI.1 and im- mune-related response criteria, and adverse events were graded with CTCAE 4.0. The EGFR-targeted CAR-T cell infusions were well-tolerated without severe toxicity. Of 11 evaluable patients, two patients obtained partial response and five had stable disease for two to eight months. The median dose of transfused CAR＋ T cells was 0.97x 10^7 cells kg J （interquar- tile range （IQR）, 0.45 to 1.09x 10^7 cells kg 1）. Pathological eradication of EGFR positive tumor cells after EGFR-targeted CAR-T cell treatment can be observed in tumor biopsies, along with the CAR-EGFR gene detected in tumor-infiltrating T cells in all four biopsied patients. The EGFR-targeted CAR-T cell therapy is safe and feasible for EGFR-positive advanced re- lapsed/refractory NSCLC.展开更多
根据猪链球菌2型(Streptococcus suis type 2,SS2)溶菌酶释放蛋白(muramidase-released protein,MRP)和胞外蛋白因子(extracellular protein factor,EPF)的基因序列,各设计合成一对引物,以猪链球菌2型江苏分离株SS2-1的基因组为模板,扩...根据猪链球菌2型(Streptococcus suis type 2,SS2)溶菌酶释放蛋白(muramidase-released protein,MRP)和胞外蛋白因子(extracellular protein factor,EPF)的基因序列,各设计合成一对引物,以猪链球菌2型江苏分离株SS2-1的基因组为模板,扩增mrp基因1 801~2 513位序列和epf 基因1 783~2 563位序列,分别构建原核表达载体pET32a-mrp 、pET32a-epf,确定诱导表达的两种蛋白都具有免疫原性后,提取阳性克隆质粒各自进行双酶切并纯化,通过PCR串联两片段,将目的片段定向克隆到表达载体pET-32a中,重组质粒转化入大肠杆菌BL21,经IPTG诱导表达分子量约为74kD的融合蛋白.用制备的两种抗血清与纯化融合蛋白进行免疫转印,结果显示融合蛋白分别具有MRP与EPF的中和表位.用融合蛋白MRP-EPF免疫新西兰兔,以最小致死量猪链球菌强毒株SS2-1攻击,兔的存活率达50%(2/4),存活率明显高于单个表达产物.证实串联表达的融合蛋白为重要的保护性抗原.展开更多
基金supported by the Science and Technology Planning Project of Beijing City (Z151100003915076)the National Natural Science Foundation of China (31270820, 81230061, 81472612, 81402566)+1 种基金the National Basic Science and Development Programme of China (2013BAI01B04)the Nursery Innovation Fund (15KMM50)
文摘The successes achieved by chimeric antigen receptor-modified T （CAR-T） cells in hematological malignancies raised the pos- sibility of their use in non-small lung cancer （NSCLC）. In this phase I clinical study （NCT01869166）, patients with epidermal growth factor receptor （EGFR）-positive （〉50% expression）, relapsed/refractory NSCLC received escalating doses of EGFR-targeted CAR-T cell infusions. The EGFR-targeted CAR-T cells were generated from peripheral blood after a 10 to 13-day in vitro expansion. Serum cytokines in peripheral blood and copy numbers of CAR-EGFR transgene in peripheral blood and in tissue biopsy were monitored periodically. Clinical responses were evaluated with RECISTI.1 and im- mune-related response criteria, and adverse events were graded with CTCAE 4.0. The EGFR-targeted CAR-T cell infusions were well-tolerated without severe toxicity. Of 11 evaluable patients, two patients obtained partial response and five had stable disease for two to eight months. The median dose of transfused CAR＋ T cells was 0.97x 10^7 cells kg J （interquar- tile range （IQR）, 0.45 to 1.09x 10^7 cells kg 1）. Pathological eradication of EGFR positive tumor cells after EGFR-targeted CAR-T cell treatment can be observed in tumor biopsies, along with the CAR-EGFR gene detected in tumor-infiltrating T cells in all four biopsied patients. The EGFR-targeted CAR-T cell therapy is safe and feasible for EGFR-positive advanced re- lapsed/refractory NSCLC.
文摘根据猪链球菌2型(Streptococcus suis type 2,SS2)溶菌酶释放蛋白(muramidase-released protein,MRP)和胞外蛋白因子(extracellular protein factor,EPF)的基因序列,各设计合成一对引物,以猪链球菌2型江苏分离株SS2-1的基因组为模板,扩增mrp基因1 801~2 513位序列和epf 基因1 783~2 563位序列,分别构建原核表达载体pET32a-mrp 、pET32a-epf,确定诱导表达的两种蛋白都具有免疫原性后,提取阳性克隆质粒各自进行双酶切并纯化,通过PCR串联两片段,将目的片段定向克隆到表达载体pET-32a中,重组质粒转化入大肠杆菌BL21,经IPTG诱导表达分子量约为74kD的融合蛋白.用制备的两种抗血清与纯化融合蛋白进行免疫转印,结果显示融合蛋白分别具有MRP与EPF的中和表位.用融合蛋白MRP-EPF免疫新西兰兔,以最小致死量猪链球菌强毒株SS2-1攻击,兔的存活率达50%(2/4),存活率明显高于单个表达产物.证实串联表达的融合蛋白为重要的保护性抗原.
